NCT02992483View on ClinicalTrials.gov

Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 12, 2017

Primary Completion Date

June 7, 2019

Study Completion Date

June 7, 2019

Conditions
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Interventions
DRUG

MIK665

MIK665

Trial Locations (8)

3084

Novartis Investigative Site, Heidelberg

20089

Novartis Investigative Site, Rozzano

24105

Novartis Investigative Site, Kiel

37007

Novartis Investigative Site, Salamanca

44093

Novartis Investigative Site, Nantes

69120

Novartis Investigative Site, Heidelberg

77030

MD Anderson Cancer Center/University of Texas MD Anderson CC, Houston

811-1395

Novartis Investigative Site, Fukuoka

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY